Reuters
Published Aug 31, 2021 04:44AM ET
By Pushkala Aripaka
(Reuters) -South Korea's SK Bioscience and Britain's GSK said on Tuesday the drugmakers had begun a late-stage trial of their COVID-19 vaccine candidate against AstraZeneca (NASDAQ:AZN)'s approved shot, the second study of its kind globally.
The AstraZeneca vaccine will take the place of a dummy shot in the trial, which will enrol about 4,000 candidates worldwide. It will test SK's candidate, GBP510, in combination with GSK's vaccine booster after positive early-stage data and a greenlight from South Korea earlier this month.
Shots from Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), J&J (NYSE:JNJ) and AstraZeneca have been approved for use in South Korea. However, its inoculation campaign has been dogged by vaccine shortages and shipment delays https://www.reuters.com/world/asia-pacific/south-korea-opens-covid-19-vaccine-reservations-all-adults-2021-08-09 amid a surging fourth wave of infections.
A potential success of the SK vaccine, the country's first domestic candidate, would help cut reliance on Western shots.
"While many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world," said GSK Chief Global Health Officer, Thomas Breuer.
The GSK-SK vaccine, if approved, would be supplied worldwide through the World Health Organization-led COVAX vaccine sharing programme, the companies said, adding that results from the study were expected in the first half next year.
Researchers in some countries may not be able give a placebo shot to people where an effective vaccine is widely available for ethical reasons. France's Valneva is also conducting a late-stage trial against AstraZeneca's shot.
The vaccine by SK, also a contract manufacturer for AstraZeneca and Novavax (NASDAQ:NVAX), is a coronavirus protein-based vaccine, while AstraZeneca's shot uses a modified version of a common-cold virus to deliver immunity-building instructions.
British drugmaker GSK, the world's largest vaccine maker by sales, has focused on supplying its adjuvant, or booster, to developers rather than make its own shot in the first leg of the vaccine race.
Shares of SK Bioscience closed up about 5% on Tuesday, while GSK was down 0.6% in morning trade.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.